focus -WSS

focus

author：Wikipedia 2025-08-11 11:41:07 - browse：1771

empty test tubes in the hand. -- first opinion coverage from STAT — Adobe

The Food and Drug Administration on Friday announced its intention to start regulating tests developed in laboratories — closing the “Theranos loophole” that has allowed inaccurate tests to slip through the cracks.

Lawmakers came close last year to passing a bill that would have given the FDA this authority, but it was ultimately rejected by Republicans who sympathized with the labs in academic medical centers and hospitals that opposed the provision. FDA Commissioner Robert Califf said at the time that if the bill failed, the agency would take matters into its own hands.

The proposed rule fulfills that promise, adding lab diagnostics to the list of devices that fall under FDA enforcement — a move that patient groups and non-lab test makers support, and that laboratories are likely to dispute. When the FDA started regulating medical devices in 1976, lab-developed tests were simple and offered mostly to local patient populations. The agency generally allowed labs to use these tests without submitting proof of their efficacy.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Covid vaccine financial winners and losers, from Pfizer to Novavax

entertainment

Wikipedia

WSS

Abortion pill Supreme Court ruling could impact entire drug industry

Christmas in the PICU brings some surprising joy

Virtual care provider acquires bankrupt Pear's prescription apps

Editas, Vertex strike deal on CRISPR

Bristol Myers buys into radiopharmaceuticals with RayzeBio

Decaf coffee targeted by food safety group under obscure FDA rule

hotspot

focus

hotspot

Drug repurposing or repositioning? The language matters

Hospitals owned by private equity see complications spike 25%

In Memoriam: Notable people who died in 2023

CRISPR gene editing developments we’re watching in 2024

Cancer drug shortages should be causing more outrage

David Ricks of Eli Lilly: best biopharma CEO of 2023

Medical records are filled with copy

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

Medical leaders decry Supreme Court decision on affirmative action

Abortion pill Supreme Court ruling could impact entire drug industry

knowledge

HCA sued by state AG for quality issues at Mission Health

Oprah kicked off a national conversation on obesity. Let's have it

Abortion pill case raises question: who can sue the FDA?

Grail spinoff by Illumina should end disastrous merger attempt

Vertex Pharmaceuticals may move headquarters in Boston

FDA's naming rule on biosimilars has undermined competition

entertainment

focus

Wikipedia

focus